Power Wheelchair Group 3 denied for failing step therapy by Humana?

Humana's specific coverage criteria for power wheelchair group3 are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applies Step Therapy to Group 3 Power Wheelchairs — and How to Navigate It

Humana's coverage policy for Group 3 complex rehab power wheelchairs applies a mobility hierarchy derived from CMS determination criteria: members are generally expected to have documented that less intensive mobility options — manual wheelchairs, scooters, or Group 2 power devices — were considered, tried, or determined to be clinically inappropriate before a Group 3 complex rehab device will be approved. A request that does not address this hierarchy typically generates a step-therapy denial.

## Why This Denial Is Appealable

The step-therapy framework is a documentation requirement, not a treatment mandate. If a lower-tier device was previously used and failed, the documentation of that failure satisfies the step. If a lower-tier device was never used because it was clinically contraindicated or functionally inadequate from the outset — for example, because the member's postural support, drive-control, or power-seating needs cannot be met by Group 2 devices — that clinical determination, properly documented by a qualified evaluator, also satisfies the requirement. The appeal is about demonstrating that the step has been effectively completed.

## Federal Appeal Framework

• Internal appeal: File within the window on the denial notice or EOB. Standard pre-service: 30 days; expedited (urgent need): 72 hours.
• External review (ACA §2719): A failed internal appeal opens the right to independent binding review. File within approximately four months of the final denial. IROs evaluate whether Humana's step-therapy application was consistent with generally accepted clinical standards for complex rehab technology.
• ERISA §503: Employer-plan members are entitled to a full-and-fair review and the complete claim file. Request it — the file will identify the specific step Humana determined was not satisfied.
• State step-therapy exception laws: Many states require payers to honor clinical exceptions to step therapy when the prescribing clinician certifies that a lower step is contraindicated or was tried and failed. Confirm whether your state law applies to your plan type.

## Documentation to Gather

• Prior device and trial records: Chart notes, therapy records, and equipment supplier records documenting prior mobility devices used, dates of use, and outcomes — including documented functional failures or adverse effects.
• Clinical exception letter: If lower-tier options were not tried because they were clinically inappropriate, a detailed letter from the prescribing physician or physiatrist explaining why — based on the specific features of the member's diagnosis and functional presentation.
• Complex rehab technology evaluation: A formal evaluation by a physical or occupational therapist and a qualified rehabilitation technology supplier documenting the specific Group 3 features required and why Group 2 or lower classification devices cannot provide them.
• Humana's step-therapy criteria: Obtain the current policy; identify each step and the corresponding exception language.

## Criteria-Mapping Structure

For each step in Humana's hierarchy, create a one-to-one mapping: either a trial-and-failure record with date and outcome, or a clinical-exception entry with the provider's name, date, and specific clinical finding supporting the exception. Attach each supporting document as a labeled exhibit. Group 3 denials overturned on step-therapy grounds almost always succeed because the clinical evaluation documents were thorough and the criteria map made the reviewer's job straightforward.